These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1506147)

  • 1. Pharmacokinetic behavior of gadoteridol injection.
    McLachlan SJ; Eaton S; De Simone DN
    Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reaction to intravenous gadoteridol.
    Shellock FG; Hahn HP; Mink JH; Itskovich E
    Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of preclinical safety evaluation of gadoteridol injection.
    Soltys RA
    Invest Radiol; 1992 Aug; 27 Suppl 1():S7-11. PubMed ID: 1506157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
    DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
    Van Wagoner M; Worah D
    Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical properties, pharmacokinetics, and biodistribution of gadoteridol injection in rats and dogs.
    Eakins MN; Eaton SM; Fisco RA; Hunt RJ; Ita CE; Katona T; Owies LM; Schramm E; Sulner JW; Thompson CW
    Acad Radiol; 1995 Jul; 2(7):584-91. PubMed ID: 9419608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
    Tweedle MF; Wedeking P; Kumar K
    Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide clinical safety assessment of gadoteridol injection: an update.
    Runge VM; Parker JR
    Eur Radiol; 1997; 7 Suppl 5():243-5. PubMed ID: 9370551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
    Livramento JB; Weidensteiner C; Prata MI; Allegrini PR; Geraldes CF; Helm L; Kneuer R; Merbach AE; Santos AC; Schmidt P; Tóth E
    Contrast Media Mol Imaging; 2006; 1(1):30-9. PubMed ID: 17193598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of gadoteridol injection: U.S. clinical trial experience.
    Olukotun AY; Parker JR; Meeks MJ; Lucas MA; Fowler DR; Lucas TR
    J Magn Reson Imaging; 1995; 5(1):17-25. PubMed ID: 7696805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.
    McDonald RJ; McDonald JS; Dai D; Schroeder D; Jentoft ME; Murray DL; Kadirvel R; Eckel LJ; Kallmes DF
    Radiology; 2017 Nov; 285(2):536-545. PubMed ID: 28640692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
    Witte RJ; Anzai LL
    AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
    Wible JH; Hynes MR
    Radiology; 2004 Oct; 233(1):158-64. PubMed ID: 15454620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers.
    Gaillard S; Kubiak C; Stolz C; Bonnemain B; Chassard D
    Invest Radiol; 2002 Apr; 37(4):161-6. PubMed ID: 11923638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.